Diabetic retinopathy clinical practice guidelines: Customized for Iranian population

Journal of Ophthalmic and Vision Research

Volumn 11, Issue 4, 2016, Pages 394-414

  Rajavi, Zhale ^a   Safi, Sare ^a   Javadi, Mohammad ^a   Azarmina, Mohsen ^a   Moradian, Siamak ^a   Entezari, Morteza ^a   Nourinia, Ramin ^a   Ahmadieh, Hamid ^a   Shirvani, Armin ^b   Shahraz, Saeid ^c   Ramezani, Alireza ^a,d   Dehghan, Mohammad ^a   Shahsavari, Mohsen ^a   Soheilian, Masoud ^a   Nikkhah, Homayoun ^a   Ziaei, Hossein ^a   Behboudi, Hasan ^e   Farrahi, Fereydoun ^f   Falavarjani, Khalil ^g   Parvaresh, Mohammad ^g   Fesharaki, Hamid ^h   Abrishami, Majid ⁱ   Shoeibi, Nasser ⁱ   Rahimi, Mansour ^j   Javadzadeh, Alireza ^k   Karkhaneh, Reza ^l   Riazi Esfahani, Mohammad ^l   Manaviat, Masoud ^m   Maleki, Alireza ⁿ   Kheiri, Bahareh ^a   Golbafian, Faegheh ^o   more..

^a SHAHID BEHESHTI UNIVERSITY OF MEDICAL SCIENCES   (Iran)

^b MINISTRY OF HEALTH AND MEDICAL EDUCATION   (Iran)

^c TUFTS MEDICAL CENTER   (United States)

^d SHAHID BEHESHTI UNIVERSITY OF MEDICAL SCIENCES   (Iran)

^e GUILAN UNIVERSITY OF MEDICAL SCIENCES   (Iran)

^f AHVAZ JUNDISHAPUR UNIVERSITY OF MEDICAL SCIENCES   (Iran)

^g IRAN UNIVERSITY OF MEDICAL SCIENCES   (Iran)

^h ISFAHAN UNIVERSITY OF MEDICAL SCIENCES   (Iran)

ⁱ MASHHAD UNIVERSITY OF MEDICAL SCIENCES   (Iran)

^j SHIRAZ UNIVERSITY OF MEDICAL SCIENCES   (Iran)

^k TABRIZ UNIVERSITY OF MEDICAL SCIENCES   (Iran)

^l TEHRAN UNIVERSITY OF MEDICAL SCIENCES   (Iran)

^m YAZD UNIVERSITY   (Iran)

ⁿ ZAHEDAN UNIVERSITY OF MEDICAL SCIENCES   (Iran)

^o UNIVERSITY OF WESTERN ONTARIO   (Canada)

more..

Author keywords

Clinical Practice Guidelines; Diabetic Retinopathy; Iran

Indexed keywords

EID: 84999273719     PISSN: 20082010     EISSN: 2008322X     Source Type: Journal    
DOI: 10.4103/2008-322X.194131     Document Type: Review

References (372)

1. Nanditha A, Ma RC, Ramachandran A, Snehalatha C, Chan JC, Chia KS, et al. Diabetes in Asia and the Pacific: Implications for the global epidemic. Diabetes Care 2016;39:472-485.
2. Shaw JE, Sicree RA, Zimmet PZ. Global estimates of the prevalence of diabetes for 2010 and 2030. Diabetes Res Clin Pract 2010;87:4-14.
3. Prevention of blindness from diabetes mellitus: report of a WHO consultation in Geneva, Switzerland, 9-11 November 2005. Available from: http://www. who. int/blindness/Prevention%20 of%20Blindness%20from%20Diabetes%20Mellitus-with-coversmall. pdf. [Last accessed on 2015 Dec 27].
4. Guariguata L, Whiting DR, Hambleton I, Beagley J, Linnenkamp U, Shaw JE. Global estimates of diabetes prevalence for 2013 and projections for 2035. Diabetes Res Clin Pract 2014;103:137-49.
5. International Diabetes Federation. IDF Diabetes Atlas. 6th ed. , 2015. Available from: http://www. diabetesatlas. org/component/ attachments/-task=download & id=116. [Last accessed on 2016 Jan 25].
6. Esteghamati A, Gouya MM, Abbasi M, Delavari A, Alikhani S, Alaedini F, et al. Prevalence of diabetes and impaired fasting glucose in the adult population of Iran: National survey of risk factors for non-communicable diseases of Iran. Diabetes Care 2008;31:96-98.
7. Hadaegh F, Bozorgmanesh MR, Ghasemi A, Harati H, Saadat N, Azizi F. High prevalence of undiagnosed diabetes and abnormal glucose tolerance in the Iranian urban population: Tehran Lipid and Glucose Study. BMC Public Health 2008;8:176.
8. Jones S, Edwards RT. Diabetic retinopathy screening: A systematic review of the economic evidence. Diabet Med 2010;27:249-256.
9. Yau JW, Rogers SL, Kawasaki R, Lamoureux EL, Kowalski JW, Bek T, et al. Global prevalence and major risk factors of diabetic retinopathy. Diabetes Care 2012;35:556-564.
10. Katibeh M, Pakravan M, Yaseri M, Pakbin M, Soleimanizad R. Prevalence and causes of visual impairment and blindness in central Iran; The Yazd Eye Study. J Ophthalmic Vis Res 2015;10:279-285.
11. Dehghan MH, Katibeh M, Ahmadieh H, Nourinia R, Yaseri M. Prevalence and risk factors for diabetic retinopathy in the 40 to 80 year-old population in Yazd, Iran: The Yazd Eye Study. J Diabetes 2015;7:139-141.
12. Judah G, Vlaev I, Gunn L, King D, King D, Valabhji J, et al. Incentives in Diabetic Eye Assessment by Screening (IDEAS): Study protocol of a three-arm randomized controlled trial using financial incentives to increase screening uptake in London. BMC Ophthalmol 2016;16:28.
13. Klein BE. Overview of epidemiologic studies of diabetic retinopathy. Ophthalmic Epidemiol 2007;14:179-183.
14. Resnikoff S, Pascolini D, Etya'ale D, Kocur I, Pararajasegaram R, Pokharel GP, et al. Global data on visual impairment in the year 2002. Bull World Health Organ 2004;82:844-851.
15. Moss SE, Klein R, Klein BE. The 14-year incidence of visual loss in a diabetic population. Ophthalmology 1998;105:998-1003.
16. Cheung N, Mitchell P, Wong TY. Diabetic retinopathy. Lancet 2010;376:124-136.
17. Klein R, Klein BE, Moss SE, Davis MD, DeMets DL. The Wisconsin epidemiologic study of diabetic retinopathy. III. Prevalence and risk of diabetic retinopathy when age at diagnosis is 30 or more years. Arch Ophthalmol 1984;102:527-532.
18. Hatef E, Fotouhi A, Hashemi H, Mohammad K, Jalali KH. Prevalence of retinal diseases and their pattern in Tehran: The Tehran eye study. Retina 2008;28:755-762.
19. Javadi MA, Katibeh M, Rafati N, Dehghan MH, Zayeri F, Yaseri M, et al. Prevalence of diabetic retinopathy in Tehran province: A population-based study. BMC Ophthalmol 2009;9:12.
20. Diabetic Retinopathy PPP. American Academy of Ophthalmology; 2012. Available from: http://www. one. aao. org/ guidelines-preferredpracticepatterns. [Last accessed on 2014 Feb 14].
21. Clinical Practice Guidelines Office for Healthcare Standards, Deputy of Curative Affairs, Ministry of Health and Medical Education, Tehran, Iran; 2015.
22. Jacobson PD. Transforming clinical practice guidelines into legislative mandates: Proceed with abundant caution. JAMA 2008;299:208-210.
23. Available from: http://www. hbi. ir/NSite/FullStory/ News/-Id=1200. [Last accessed on 2013 Sep 18].
24. Fifth Five Year Development Plan of the Islamic Republic of Iran (1390-1394). Available at: http://rc. majlis. ir/fa/law/ show/790196. [Last assessed on 2013 Sep 7].
25. Appraisal of Guidelines for Research and Evaluation. Available from: http://www. agreetrust. org/. [Last accessed on 2016 Jan 10].
26. The Royal College of Ophthalmologists. Diabetic Retinopathy Guidelines; 2012. Available from: http://www. rcophth. ac. uk. [Last accessed on 2014 Feb 12].
27. The Australian Diabetes Society. Guidelines for the Management of Diabetic Retinopathy; 2008. Available from: http://www. nhmrc. gov. au/-files-nhmrc/publications/attachments/di15. pdf. [Last accessed on 2014 Feb 18].
28. New Zealand Guidelines Group. Handbook for the Preparation of Explicit Evidence-Based Clinical Practice Guidelines: New Zealand Guidelines Group; 2001.
29. ENSPDR. English National Screening Programme for Diabetic Retinopathy; 2011. Available from: http://www. retinalscreening. nhs. uk. [Last accessed on 2014 Mar 10].
30. SDRSC. Scottish Diabetic Retinopathy Screening Collaborative; 2011. Available from: http://www. ndrs. scot. nhs. uk/. [Last accessed on 2014 Mar 10].
31. DRSSW. Diabetic Retinopathy Screening Service for Wales; 2011. Available from: http://www. wales. nhs. uk/sitesplus/864/ page/42582.
32. NIDRSP. Northern Ireland DR Screening Programme Annual Report 2008-2009; 2010.
33. Hutchinson A, McIntosh A, Peters J, O'Keeffe C, Khunti K, Baker R, et al. Effectiveness of screening and monitoring tests for diabetic retinopathy-A systematic review. Diabet Med 2000;17:495-506.
34. National Institute for Clinical Excellence. Diabetic retinopathy-Early Management and Screening. London, UK: National Institute for Clinical Excellence; 2001.
35. Moss SE, Klein R, Kessler SD, Richie KA. Comparison between ophthalmoscopy and fundus photography in determining severity of diabetic retinopathy. Ophthalmology 1985;92:62-67.
36. Javitt JC, Aiello LP, Bassi LJ, Chiang YP, Canner JK. Detecting and treating retinopathy in patients with type I diabetes mellitus. Savings associated with improved implementation of current guidelines. American Academy of Ophthalmology. Ophthalmology 1991;98:1565-1573.
37. Management of Diabetic Retinopathy. Clinical Practice Guidelines. Canberra, Commonwealth Department of Health and Family Services; 1997. p. 1-94.
38. Pandit RJ, Taylor R. Mydriasis and glaucoma: Exploding the myth. A systematic review. Diabet Med 2000;17:693-699.
39. Liew G, Mitchell P, Wang JJ, Wong TY. Fundoscopy: To dilate or not to dilate? BMJ 2006;332:3.
40. Javitt JC, Aiello LP, Chiang Y, Ferris FL 3rd, Canner JK, Greenfield S. Preventive eye care in people with diabetes is cost-saving to the federal government. Implications for health-care reform. Diabetes Care 1994;17:909-917.
41. Dasbach EJ, Fryback DG, Newcomb PA, Klein R, Klein BE. Cost-effectiveness of strategies for detecting diabetic retinopathy. Med Care 1991;29:20-39.
42. Jacob J, Stead J, Sykes J, Taylor D, Tooke JE. A report on the use of technician ophthalmoscopy combined with the use of the Canon non-mydriatic camera in screening for diabetic retinopathy in the community. Diabet Med 1995;12:419-425.
43. Wolfs RC, Grobbee DE, Hofman A, de Jong PT. Risk of acute angle-closure glaucoma after diagnostic mydriasis in nonselected subjects: The Rotterdam Study. Invest Ophthalmol Vis Sci 1997;38:2683-2687.
44. Mapstone R, Clark CV. Prevalence of diabetes in glaucoma. Br Med J (Clin Res Ed) 1985;291:93-95.
45. Olsen BS, Sjølie A, Hougaard P, Johannesen J, Borch-Johnsen K, Marinelli K, et al. A 6-year nationwide cohort study of glycaemic control in young people with type 1 diabetes. Risk markers for the development of retinopathy, nephropathy and neuropathy. Danish Study Group of Diabetes in Childhood. J Diabetes Complications 2000;14:295-300.
46. Klein R, Klein BE, Moss SE, Cruickshanks KJ. The Wisconsin Epidemiologic Study of Diabetic Retinopathy: XVII. The 14-year incidence and progression of diabetic retinopathy and associated risk factors in type 1 diabetes. Ophthalmology 1998;105:1801-1815.
47. Casano RA, Bykhovskaya Y, Johnson DF, Hamon M, Torricelli F, Bigozzi M, et al. Hearing loss due to the mitochondrial A1555G mutation in Italian families. Am J Med Genet 1998;79:388-391.
48. Mitchell P, Moffitt PS, Beaumont P. Prevalence of vision-threatening diabetic retinopathy in Newcastle, Australia. Tohoku J Exp Med 1983;141 Suppl:379-383.
49. Mitchell P. The prevalence of diabetic retinopathy: A study of 1300 diabetics from Newcastle and the Hunter Valley. Aust J Ophthalmol 1980;8:241-246.
50. Mitchell P, Moffitt P. Update and implications from the Newcastle diabetic retinopathy study. Aust N Z J Ophthalmol 1990;18:13-17.
51. Klein R, Klein BE, Moss SE, Davis MD, DeMets DL. The Wisconsin epidemiologic study of diabetic retinopathy. II. Prevalence and risk of diabetic retinopathy when age at diagnosis is less than 30 years. Arch Ophthalmol 1984;102:520-526.
52. Varma R, Torres M, Peña F, Klein R, Azen SP; Los Angeles Latino Eye Study Group. Prevalence of diabetic retinopathy in adult Latinos: The Los Angeles Latino eye study. Ophthalmology 2004;111:1298-1306.
53. Hirai FE, Knudtson MD, Klein BE, Klein R. Clinically significant macular edema and survival in type 1 and type 2 diabetes. Am J Ophthalmol 2008;145:700-706.
54. West SK, Klein R, Rodriguez J, Muñoz B, Broman AT, Sanchez R, et al. Diabetes and diabetic retinopathy in a Mexican-American population: Proyecto VER. Diabetes Care 2001;24:1204-1209.
55. The relationship of glycemic exposure (HbA1c) to the risk of development and progression of retinopathy in the diabetes control and complications trial. Diabetes 1995;44:968-983.
56. Intensive blood-glucose control with sulphonylureas or insulin compared with conventional treatment and risk of complications in patients with type 2 diabetes (UKPDS 33). UK Prospective Diabetes Study (UKPDS) Group. Lancet 1998;352:837-853.
57. Stratton IM, Cull CA, Adler AI, Matthews DR, Neil HA, Holman RR. Additive effects of glycaemia and blood pressure exposure on risk of complications in type 2 diabetes: A prospective observational study (UKPDS 75). Diabetologia 2006;49:1761-1769.
58. Matthews DR, Stratton IM, Aldington SJ, Holman RR, Kohner EM; UK Prospective Diabetes Study Group. Risks of progression of retinopathy and vision loss related to tight blood pressure control in type 2 diabetes mellitus: UKPDS 69. Arch Ophthalmol 2004;122:1631-1640.
59. Klein R, Palta M, Allen C, Shen G, Han DP, D'Alessio DJ. Incidence of retinopathy and associated risk factors from time of diagnosis of insulin-dependent diabetes. Arch Ophthalmol 1997;115:351-356.
60. Wang PH, Lau J, Chalmers TC. Meta-analysis of effects of intensive blood-glucose control on late complications of type I diabetes. Lancet 1993;341:1306-1309.
61. Massin P, Erginay A, Mercat-Caudal I, Vol S, Robert N, Reach G, et al. Prevalence of diabetic retinopathy in children and adolescents with type-1 diabetes attending summer camps in France. Diabetes Metab 2007;33:284-289.
62. Gallego PH, Craig ME, Hing S, Donaghue KC. Role of blood pressure in development of early retinopathy in adolescents with type 1 diabetes: Prospective cohort study. BMJ 2008;337:a918.
63. Mohamed Q, Gillies MC, Wong TY. Management of diabetic retinopathy: A systematic review. JAMA 2007;298:902-916.
64. Stratton IM, Kohner EM, Aldington SJ, Turner RC, Holman RR, Manley SE, et al. UKPDS 50: Risk factors for incidence and progression of retinopathy in type II diabetes over 6 years from diagnosis. Diabetologia 2001;44:156-163.
65. Schrier RW, Estacio RO, Esler A, Mehler P. Effects of aggressive blood pressure control in normotensive type 2 diabetic patients on albuminuria, retinopathy and strokes. Kidney Int 2002;61:1086-1097.
66. ACCORD Study Group; ACCORD Eye Study Group, Chew EY, Ambrosius WT, Davis MD, Danis RP, Gangaputra S, et al. Effects of medical therapies on retinopathy progression in type 2 diabetes. N Engl J Med 2010;363:233-244.
67. Keech AC, Mitchell P, Summanen PA, O'Day J, Davis TM, Moffitt MS, et al. Effect of fenofibrate on the need for laser treatment for diabetic retinopathy (FIELD study): A randomised controlled trial. Lancet 2007;370:1687-1697.
68. Chew EY, Klein ML, Ferris FL 3rd, Remaley NA, Murphy RP, Chantry K, et al. Association of elevated serum lipid levels with retinal hard exudate in diabetic retinopathy. Early Treatment Diabetic Retinopathy Study (ETDRS) Report 22. Arch Ophthalmol 1996;114:1079-1084.
69. Sen K, Misra A, Kumar A, Pandey RM. Simvastatin retards progression of retinopathy in diabetic patients with hypercholesterolemia. Diabetes Res Clin Pract 2002;56:1-11.
70. Gupta A, Gupta V, Thapar S, Bhansali A. Lipid-lowering drug atorvastatin as an adjunct in the management of diabetic macular edema. Am J Ophthalmol 2004;137:675-682.
71. Klein R, Sharrett AR, Klein BE, Moss SE, Folsom AR, Wong TY, et al. The association of atherosclerosis, vascular risk factors, and retinopathy in adults with diabetes: The atherosclerosis risk in communities study. Ophthalmology 2002;109:1225-1234.
72. Ferris FL 3rd, Chew EY, Hoogwerf BJ. Serum lipids and diabetic retinopathy. Early Treatment Diabetic Retinopathy Study Research Group. Diabetes Care 1996;19:1291-1293.
73. Chew EY. Diabetic retinopathy and lipid abnormalities. Curr Opin Ophthalmol 1997;8:59-62.
74. Su DH, Yeo KT. Diabetic retinopathy and serum lipids. Singapore Med J 2000;41:295-297.
75. Cusick M, Chew EY, Chan CC, Kruth HS, Murphy RP, Ferris FL 3rd. Histopathology and regression of retinal hard exudates in diabetic retinopathy after reduction of elevated serum lipid levels. Ophthalmology 2003;110:2126-2133.
76. Curtis TM, Scholfield CN. The role of lipids and protein kinase Cs in the pathogenesis of diabetic retinopathy. Diabetes Metab Res Rev 2004;20:28-43.
77. Cohen RA, Hennekens CH, Christen WG, Krolewski A, Nathan DM, Peterson MJ, et al. Determinants of retinopathy progression in type 1 diabetes mellitus. Am J Med 1999;107:45-51.
78. El-Asrar AM, Al-Rubeaan KA, Al-Amro SA, Kangave D, Moharram OA. Risk factors for diabetic retinopathy among Saudi diabetics. Int Ophthalmol 1998-1999;22:155-161.
79. Lyons TJ, Jenkins AJ, Zheng D, Lackland DT, McGee D, Garvey WT, et al. Diabetic retinopathy and serum lipoprotein subclasses in the DCCT/EDIC cohort. Invest Ophthalmol Vis Sci 2004;45:910-918.
80. Uçgun NI, Yildirim Z, Kiliç N, Gürsel E. The importance of serum lipids in exudative diabetic macular edema in type 2 diabetic patients. Ann N Y Acad Sci 2007;1100:213-217.
81. van Leiden HA, Dekker JM, Moll AC, Nijpels G, Heine RJ, Bouter LM, et al. Blood pressure, lipids, and obesity are associated with retinopathy: The Hoorn study. Diabetes Care 2002;25:1320-1325.
82. Penno G, Solini A, Zoppini G, Orsi E, Zerbini G, Trevisan R, et al. Rate and determinants of association between advanced retinopathy and chronic kidney disease in patients with type 2 diabetes: The Renal Insufficiency and Cardiovascular Events (RIACE) Italian multicenter study. Diabetes Care 2012;35:2317-2323.
83. Kaur H, Donaghue KC, Chan AK, Benitez-Aguirre P, Hing S, Lloyd M, et al. Vitamin D deficiency is associated with retinopathy in children and adolescents with type 1 diabetes. Diabetes Care 2011;34:1400-1402.
84. Ahmadieh H, Azar ST, Lakkis N, Arabi A. Hypovitaminosis D in patients with type 2 diabetes mellitus: A relation to disease control and complications. ISRN Endocrinol 2013;2013:641098.
85. Aksoy H, Akçay F, Kurtul N, Baykal O, Avci B. Serum 1, 25 dihydroxy Vitamin D (1, 25(OH) 2D3), 25 hydroxy vitamin D (25(OH) D) and parathormone levels in diabetic retinopathy. Clin Biochem 2000;33:47-51.
86. Donaghue K, Chiarelli F, Trotta D, Allgrove J, Dahl-Jorgensen K. ISPAD clinical practice consensus guideline: Microvascular and macrovasculat complications associated with diabetes in children and adolescents. Pediatr Diabetes 2009;19(Suppl 2):195-203.
87. Review of Public Health guidance (PH 10)-Smoking cessation services in primary care, pharmacies, local authorities and workplaces, particularly for manual working groups, pregnant women and hard to reach communities. Available from: https://www. nice. org. uk/guidance/ph 10/documents/ smoking-cessation-services-in-primary-care-pharmacies-localauthorities-and-workplaces-particularly-for-manual-workinggroups-pregnant-women-and-hard-to-reach-communities-revi ew-proposal-consultation2. [Last accessed on 2013 Feb 18].
88. Moss SE, Klein R, Klein BE. Association of cigarette smoking with diabetic retinopathy. Diabetes Care 1991;14:119-126.
89. Karamanos B, Porta M, Songini M, Metelko Z, Kerenyi Z, Tamas G, et al. Different risk factors of microangiopathy in patients with type I diabetes mellitus of short versus long duration. The EURODIAB IDDM Complications Study. Diabetologia 2000;43:348-355.
90. Li R, Zhang P, Barker LE, Chowdhury FM, Zhang X. Cost-effectiveness of interventions to prevent and control diabetes mellitus: A systematic review. Diabetes Care 2010;33:1872-1894.
91. Moss SE, Klein R, Klein BE. Cigarette smoking and ten-year progression of diabetic retinopathy. Ophthalmology 1996;103:1438-1442.
92. Martin TL, Selby JV, Zhang D. Physician and patient prevention practices in NIDDM in a large urban managed-care organization. Diabetes Care 1995;18:1124-1132.
93. Telmer S, Christiansen JS, Andersen AR, Nerup J, Deckert T. Smoking habits and prevalence of clinical diabetic microangiopathy in insulin-dependent diabetics. Acta Med Scand 1984;215:63-68.
94. Klein R, Klein BE, Davis MD. Is cigarette smoking associated with diabetic retinopathy? Am J Epidemiol 1983;118:228-238.
95. Klein BE, Moss SE, Klein R. Effect of pregnancy on progression of diabetic retinopathy. Diabetes Care 1990;13:34-40.
96. Hemachandra A, Ellis D, Lloyd CE, Orchard TJ. The influence of pregnancy on IDDM complications. Diabetes Care 1995;18:950-954.
97. Sunness JS. The pregnant woman's eye. Surv Ophthalmol 1988;32:219-238.
98. Four risk factors for severe visual loss in diabetic retinopathy. The third report from the Diabetic Retinopathy Study. The Diabetic Retinopathy Study Research Group. Arch Ophthalmol 1979;97:654-655.
99. Chan WC, Lim LT, Quinn MJ, Knox FA, McCance D, Best RM. Management and outcome of sight-threatening diabetic retinopathy in pregnancy. Eye 2004;18:826-832.
100. Rahman W, Rahman FZ, Yassin S, Al-Suleiman SA, Rahman J. Progression of retinopathy during pregnancy in type 1 diabetes mellitus. Clin Experiment Ophthalmol 2007;35:231-236.
101. Chew EY, Mills JL, Metzger BE, Remaley NA, Jovanovic-Peterson L, Knopp RH, et al. Metabolic control and progression of retinopathy. The Diabetes in Early Pregnancy Study. National Institute of Child Health and Human Development Diabetes in Early Pregnancy Study. Diabetes Care 1995;18:631-637.
102. Diabetes Control and Complications Trial Research Group. Effect of pregnancy on microvascular complications in the diabetes control and complications trial. The Diabetes Control and Complications Trial Research Group. Diabetes Care 2000;23:1084-1091.
103. Rema M, Saravanan G, Deepa R, Mohan V. Familial clustering of diabetic retinopathy in South Indian type 2 diabetic patients. Diabet Med 2002;19:910-916.
104. Haffner SM. Epidemiology of type 2 diabetes: Risk factors. Diabetes Care 1998;21(Suppl 3):C3-6.
105. Warpeha KM, Chakravarthy U. Molecular genetics of microvascular disease in diabetic retinopathy. Eye 2003;17:305-311.
106. Agardh E, Gaur LK, Lernmark A, Agardh CD. HLA-DRB1,-DQA1, and-DQB1 subtypes or ACE gene polymorphisms do not seem to be risk markers for severe retinopathy in younger Type 1 diabetic patients. J Diabetes Complications 2004;18:32-36.
107. Kumaramanickavel G, Sripriya S, Ramprasad VL, Upadyay NK, Paul PG, Sharma T. Z-2 aldose reductase allele and diabetic retinopathy in India. Ophthalmic Genet 2003;24:41-48.
108. Looker HC, Nelson RG, Chew E, Klein R, Klein BE, Knowler WC, et al. Genome-wide linkage analyses to identify Loci for diabetic retinopathy. Diabetes 2007;56:1160-1166.
109. Hallman DM, Boerwinkle E, Gonzalez VH, Klein BE, Klein R, Hanis CL. A genome-wide linkage scan for diabetic retinopathy susceptibility genes in Mexican Americans with type 2 diabetes from Starr County, Texas. Diabetes 2007;56:1167-1173.
110. Imperatore G, Hanson RL, Pettitt DJ, Kobes S, Bennett PH, Knowler WC. Sib-pair linkage analysis for susceptibility genes for microvascular complications among Pima Indians with type 2 diabetes. Pima Diabetes Genes Group. Diabetes 1998;47:821-830.
111. Olmos P, Bastías MJ, Vollrath V, Toro L, Trincado A, Salinas P, et al. C(-106) T polymorphism of the aldose reductase gene and the progression rate of diabetic retinopathy. Diabetes Res Clin Pract 2006;74:175-182.
112. Kumaramanickavel G, Ramprasad VL, Sripriya S, Upadyay NK, Paul PG, Sharma T. Association of Gly82Ser polymorphism in the RAGE gene with diabetic retinopathy in type II diabetic Asian Indian patients. J Diabetes Complications 2002;16:391-394.
113. Beránek M, Kanková K, Benes P, Izakovicová-Hollá L, Znojil V, Hájek D, et al. Polymorphism R25P in the gene encoding transforming growth factor-beta (TGF-beta1) is a newly identified risk factor for proliferative diabetic retinopathy. Am J Med Genet 2002 15;109:278-283.
114. Awata T, Inoue K, Kurihara S, Ohkubo T, Watanabe M, Inukai K, et al. A common polymorphism in the 5'-untranslated region of the VEGF gene is associated with diabetic retinopathy in type 2 diabetes. Diabetes 2002;51:1635-1639.
115. Chen LK, Buchan AM, Hwang SJ, Hinkle J. Cataract surgery after acute stroke: Maybe more than a coincidence. Stroke 2006;37:766-767.
116. Errera FI, Canani LH, Silva ME, Yeh E, Takahashi W, Santos KG, et al. Functional vascular endothelial growth factor-634G>C SNP is associated with proliferative diabetic retinopathy: A case-control study in a Brazilian population of European ancestry. Diabetes Care 2007;30:275-279.
117. Suganthalakshmi B, Anand R, Kim R, Mahalakshmi R, Karthikprakash S, Namperumalsamy P, et al. Association of VEGF and eNOS gene polymorphisms in type 2 diabetic retinopathy. Mol Vis 2006;12:336-341.
118. Taverna MJ, Sola A, Guyot-Argenton C, Pacher N, Bruzzo F, Slama G, et al. Taq I polymorphism of the Vitamin D receptor and risk of severe diabetic retinopathy. Diabetologia 2002;45:436-442.
119. Zintzaras E, Chatzoulis DZ, Karabatsas CH, Stefanidis I. The relationship between C677T methylenetetrahydrofolate reductase gene polymorphism and retinopathy in type 2 diabetes: A meta-analysis. J Hum Genet 2005;50:267-275.
120. Rietveld I, Ikram MK, Vingerling JR, Hofman A, Pols HA, Lamberts SW, et al. An igf-I gene polymorphism modifies the risk of diabetic retinopathy. Diabetes 2006;55:2387-2391.
121. Nikzamir A, Rashidi A, Esteghamati A, Nakhjavani M, Golmohammadi T, Khalilzadeh O. The relationship between ACE gene insertion/deletion polymorphism and diabetic retinopathy in Iranian patients with type 2 diabetes. Ophthalmic Genet 2010;31:108-113.
122. Feghhi M, Nikzamir A, Esteghamati A, Mahmoudi T, Yekaninejad MS. Relationship of vascular endothelial growth factor (VEGF) +405 G/C polymorphism and proliferative retinopathy in patients with type 2 diabetes. Transl Res 2011;158:85-91.
123. Jeganathan VS, Wang JJ, Wong TY. Ocular associations of diabetes other than diabetic retinopathy. Diabetes Care 2008;31:1905-1912.
124. Tan GS, Wong TY, Fong CW, Aung T; Singapore Malay Eye Study. Diabetes, metabolic abnormalities, and glaucoma. Arch Ophthalmol 2009;127:1354-1361.
125. Xu L, Xie XW, Wang YX, Jonas JB. Ocular and systemic factors associated with diabetes mellitus in the adult population in rural and urban China. The Beijing Eye Study. Eye (Lond) 2009;23:676-682.
126. Quigley HA. Can diabetes be good for glaucoma? Why can't we believe our own eyes (or data)? Arch Ophthalmol 2009;127:227-229.
127. Davis MD, Fisher MR, Gangnon RE, Barton F, Aiello LM, Chew EY, et al. Risk factors for high-risk proliferative diabetic retinopathy and severe visual loss: Early Treatment Diabetic Retinopathy Study Report #18. Invest Ophthalmol Vis Sci 1998;39:233-252.
128. Wilkinson CP, Ferris FL 3rd, Klein RE, Lee PP, Agardh CD, Davis M, et al. Proposed international clinical diabetic retinopathy and diabetic macular edema disease severity scales. Ophthalmology 2003;110:1677-1682.
129. Ginsburg LH, Aiello LM. Diabetic retinopathy: Classification, progression and management. Focal Points (AAO). Vol. XI. American Academy of Ophthalmology; 1993. p. 1-14.
130. Thomas RK, Melton NR. Pupillary dilation: A view from the trenches. J Am Optom Assoc 1993;64:612.
131. American Diabetes Association. Diabetic retinopathy. Diabetes Care 2000;23(Suppl 1):S73-6.
132. American Academy of Ophthalmology. Preferred Practice Pattern: Diabetic Retinopathy. San Francisco (CA): American Academy of Ophthalmology; 2003.
133. Classification of diabetic retinopathy from fluorescein angiograms. ETDRS report number 11. Early Treatment Diabetic Retinopathy Study Research Group. Ophthalmology 1991;98(Suppl 5):807-822.
134. Photocoagulation for diabetic macular edema. Early Treatment Diabetic Retinopathy Study report number 1. Early Treatment Diabetic Retinopathy Study research group. Arch Ophthalmol 1985;103:1796-1806.
135. Focal photocoagulation treatment of diabetic macular edema. Relationship of treatment effect to fluorescein angiographic and other retinal characteristics at baseline: ETDRS report no 19. Early Treatment Diabetic Retinopathy Study Research Group. Arch Ophthalmol 1995;113:1144-1155.
136. Bloome MA. Fluorescein angiography: Risks. Vision Res 1980;20:1083-1097.
137. Pacurariu RI. Low incidence of side effects following intravenous fluorescein angiography. Ann Ophthalmol 1982;14:32-36.
138. Yannuzzi LA, Rohrer KT, Tindel LJ, Sobel RS, Costanza MA, Shields W, et al. Fluorescein angiography complication survey. Ophthalmology 1986;93:611-617.
139. Karhunen U, Raitta C, Kala R. Adverse reactions to fluorescein angiography. Acta Ophthalmol (Copenh) 1986;64:282-286.
140. Kwiterovich KA, Maguire MG, Murphy RP, Schachat AP, Bressler NM, Bressler SB, et al. Frequency of adverse systemic reactions after fluorescein angiography. Results of a prospective study. Ophthalmology 1991;98:1139-1142.
141. Weaver DT, Herman DC. A contraindication to injection of intravenous fluorescein. Am J Ophthalmol 1990;109:490-491.
142. Brown RE Jr. , Sabates R, Drew SJ. Metoclopramide as prophylaxis for nausea and vomiting induced by fluorescein. Arch Ophthalmol 1987;105:658-659.
143. Fluorescein and Indocyanine Green Angiography Guidelines. The Royal Australian and New Zealand College of Ophthalmologists. Australia: The Royal Australian and New Zealand College of Ophthalmologists; 2007. p. 1-6.
144. Kong M, Lee MY, Ham DI. Ultrawide-field fluorescein angiography for evaluation of diabetic retinopathy. Korean J Ophthalmol 2012;26:428-431.
145. Wessel MM, Aaker GD, Parlitsis G, Cho M, D'Amico DJ, Kiss S. Ultra-wide-field angiography improves the detection and classification of diabetic retinopathy. Retina 2012;32:785-791.
146. Virgili G, Menchini F, Casazza G, Hogg R, Das RR, Wang X, et al. Optical coherence tomography (OCT) for detection of macular oedema in patients with diabetic retinopathy. Cochrane Database Syst Rev 2015;1:CD008081.
147. Virgili G, Menchini F, Dimastrogiovanni AF, Rapizzi E, Menchini U, Bandello F, et al. Optical coherence tomography versus stereoscopic fundus photography or biomicroscopy for diagnosing diabetic macular edema: A systematic review. Invest Ophthalmol Vis Sci 2007;48:4963-4973.
148. McDonald HR, Williams GA, Scott IU, Haller JA, Maguire AM, Marcus DM; American Academy of Ophthalmology; Ophthalmic Technology Assessment Committee Retina Panel. Laser scanning imaging for macular disease: A report by the American Academy of Ophthalmology. Ophthalmology 2007;114:1221-1228.
149. Panozzo G, Gusson E, Parolini B, Mercanti A. Role of OCT in the diagnosis and follow up of diabetic macular edema. Semin Ophthalmol 2003;18:74-81.
150. Ozdek SC, Erdinç MA, Gürelik G, Aydin B, Bahçeci U, Hasanreisoglu B. Optical coherence tomographic assessment of diabetic macular edema: Comparison with fluorescein angiographic and clinical findings. Ophthalmologica 2005;219:86-92.
151. Massin P, Girach A, Erginay A, Gaudric A. Optical coherence tomography: A key to the future management of patients with diabetic macular oedema. Acta Ophthalmol Scand 2006;84:466-474.
152. Browning DJ, McOwen MD, Bowen RM Jr. , O'Marah TL. Comparison of the clinical diagnosis of diabetic macular edema with diagnosis by optical coherence tomography. Ophthalmology 2004;111:712-715.
153. Kang SW, Park CY, Ham DI. The correlation between fluorescein angiographic and optical coherence tomographic features in clinically significant diabetic macular edema. Am J Ophthalmol 2004;137:313-322.
154. Jaffe GJ, Caprioli J. Optical coherence tomography to detect and manage retinal disease and glaucoma. Am J Ophthalmol 2004;137:156-169.
155. Gaucher D, Tadayoni R, Erginay A, Haouchine B, Gaudric A, Massin P. Optical coherence tomography assessment of the vitreoretinal relationship in diabetic macular edema. Am J Ophthalmol 2005;139:807-813.
156. Sánchez-Tocino H, Alvarez-Vidal A, Maldonado MJ, Moreno-Montanes J, Garcia-Layana A. Retinal thickness study with optical coherence tomography in patients with diabetes. Invest Ophthalmol Vis Sci 2002;43:1588-1594.
157. Kaiser PK, Riemann CD, Sears JE, Lewis H. Macular traction detachment and diabetic macular edema associated with posterior hyaloidal traction. Am J Ophthalmol 2001;131:44-49.
158. Strøm C, Sander B, Larsen N, Larsen M, Lund-Andersen H. Diabetic macular edema assessed with optical coherence tomography and stereo fundus photography. Invest Ophthalmol Vis Sci 2002;43:241-245.
159. Muscat S, Parks S, Kemp E, Keating D. Repeatability and reproducibility of macular thickness measurements with the Humphrey OCT system. Invest Ophthalmol Vis Sci 2002;43:490-495.
160. Massin P, Vicaut E, Haouchine B, Erginay A, Paques M, Gaudric A. Reproducibility of retinal mapping using optical coherence tomography. Arch Ophthalmol 2001;119:1135-1142.
161. Hee MR, Puliafito CA, Duker JS, Reichel E, Coker JG, Wilkins JR, et al. Topography of diabetic macular edema with optical coherence tomography. Ophthalmology 1998;105:360-370.
162. Otani T, Kishi S, Maruyama Y. Patterns of diabetic macular edema with optical coherence tomography. Am J Ophthalmol 1999;127:688-693.
163. Soliman W, Sander B, Hasler PW, Larsen M. Correlation between intraretinal changes in diabetic macular oedema seen in fluorescein angiography and optical coherence tomography. Acta Ophthalmol 2008;86:34-39.
164. Otani T, Kishi S. Correlation between optical coherence tomography and fluorescein angiography findings in diabetic macular edema. Ophthalmology 2007;114:104-107.
165. Alkuraya H, Kangave D, Abu El-Asrar AM. The correlation between optical coherence tomographic features and severity of retinopathy, macular thickness and visual acuity in diabetic macular edema. Int Ophthalmol 2005;26:93-99.
166. Diabetic Retinopathy Clinical Research Network, Browning DJ, Glassman AR, Aiello LP, Beck RW, Brown DM, et al. Relationship between optical coherence tomography-measured central retinal thickness and visual acuity in diabetic macular edema. Ophthalmology 2007;114:525-536.
167. Brown JC, Solomon SD, Bressler SB, Schachat AP, DiBernardo C, Bressler NM. Detection of diabetic foveal edema: Contact lens biomicroscopy compared with optical coherence tomography. Arch Ophthalmol 2004;122:330-335.
168. Moreira RO, Trujillo FR, Meirelles RM, Ellinger VC, Zagury L. Use of optical coherence tomography (OCT) and indirect ophthalmoscopy in the diagnosis of macular edema in diabetic patients. Int Ophthalmol 2001;24:331-336.
169. Polito A, Shah SM, Haller JA, Zimmer-Galler I, Zeimer R, Campochiaro PA, et al. Comparison between retinal thickness analyzer and optical coherence tomography for assessment of foveal thickness in eyes with macular disease. Am J Ophthalmol 2002;134:240-251.
170. Martidis A, Duker JS, Greenberg PB, Rogers AH, Puliafito CA, Reichel E, et al. Intravitreal triamcinolone for refractory diabetic macular edema. Ophthalmology 2002;109:920-927.
171. Hassenstein A, Meyer CH. Clinical use and research applications of Heidelberg retinal angiography and spectral-domain optical coherence tomography-A review. Clin Experiment Ophthalmol 2009;37:130-143.
172. Fritsche P, van der Heijde R, Suttorp-Schulten MS, Polak BC. Retinal thickness analysis (RTA): An objective method to assess and quantify the retinal thickness in healthy controls and in diabetics without diabetic retinopathy. Retina 2002;22:768-771.
173. Guan K, Hudson C, Flanagan JG. Comparison of Heidelberg retina tomograph II and retinal thickness analyzer in the assessment of diabetic macular edema. Invest Ophthalmol Vis Sci 2004;45:610-616.
174. SIGN Guideline 116. Management of Diabetes. A National Clinical Guideline. Available from: http://www. sign. ac. uk/pdf/sign116. pdf. [Last accessed on 2012 Jan 14].
175. Diabetic Retinopathy Study Research Group. Report 7. A modification of the Airlie House classification of diabetic retinopathy. Invest Ophthalmol Vis Sci 1981;21:210-226.
176. Grading diabetic retinopathy from stereoscopic color fundus photographs-An extension of the modified Airlie House classification. ETDRS report number 10. Early Treatment Diabetic Retinopathy Study Research Group. Ophthalmology 1991;98(Suppl 5):786-806.
177. Royal College of Ophthalmologists. Guidelines for the Management of Diabetic Retinopathy. London: Royal College of Ophthalmologists; 1997.
178. Early photocoagulation for diabetic retinopathy. ETDRS report number 9. Early Treatment Diabetic Retinopathy Study Research Group. Ophthalmology 1991;98(Suppl 5):766-785.
179. Aldington SJ, Kohner EM, Meuer S, Klein R, Sjølie AK. Methodology for retinal photography and assessment of diabetic retinopathy: The EURODIAB IDDM complications study. Diabetologia 1995;38:437-444.
180. Kohner EM, Stratton IM, Aldington SJ, Turner RC, Matthews DR. Microaneurysms in the development of diabetic retinopathy (UKPDS 42). UK Prospective Diabetes Study Group. Diabetologia 1999;42:1107-1112.
181. Bresnick GH, Mukamel DB, Dickinson JC, Cole DR. A screening approach to the surveillance of patients with diabetes for the presence of vision-threatening retinopathy. Ophthalmology 2000;107:19-24.
182. National Health Service. Photographic Grading and Disease Management; 2000. [Last assessed on 2013 Mar 15].
183. Fukuda M. Clinical arrangement of classification of diabetic retinopathy. Tohoku J Exp Med 1983;141:331-335.
184. Cahill M, O'Toole L, Acheson RW. Hormone replacement therapy and retinal vein occlusion. Eye 1999;13(Pt 6):798-800.
185. Global Diabetic Retinopathy Project Task Force and Invitational Workshop. International Clinical Diabetic Retinopathy and Diabetic Macular Edema Disease Severity Scales. Available from: http://www. aao. org/clinical-statement/ international-clinical-classification-system-diabe. [Last assessed on 2016 Jan 25].
186. Kohner EM, Porta M, World Health Organization. Screening for Diabetic Retinopathy: A Field Guide-book. Copenhagen: World Health Organization; 1992. p. 1-51.
187. Ferris FL. Early photocoagulation in patients with either type 1 or type 2 diabetes. Trans Am Ophthalmol Soc 1996;14:505-537.
188. Menchini U, Cappelli S, Virgili G. Cataract surgery and diabetic retinopathy. Semin Ophthalmol 2003;18:103-108.
189. Lovestam-Adrian M, Agardh CD, Torffvit O, Agardh E. Type 1 diabetes patients with severe non-proliferative retinopathy may benefit from panretinal photocoagulation. Acta Ophthalmol Scand 2003;81:221-225.
190. Treatment techniques and clinical guidelines for photocoagulation of diabetic macular edema. Early Treatment Diabetic Retinopathy Study Report Number 2. Early Treatment Diabetic Retinopathy Study Research Group. Ophthalmology 1987;94:761-774.
191. Diabetic Retinopathy Study Research Group. Indications for photocoagulation treatment of diabetic retinopathy: Diabetic Retinopathy Study Report number 14. Int Ophthalmol Clin 1987;27:239-253.
192. Early Treatment Diabetic Retinopathy Study Research Group. Early photocoagulation for diabetic retinopathy. ETDRS report number 9. Ophthalmology 1991;98:766-785.
193. Ferris F. Early photocoagulation in patients with either type I or type II diabetes. Trans Am Ophthalmol Soc 1996;94:505-537.
194. Zaluski S, Marcil G, Lamer L, Lambert J. Study of the visual field using automated static perimetry following panretinal photocoagulation in the diabetic. J Fr Ophtalmol 1986;9:395-401.
195. Buckley SA, Jenkins L, Benjamin L. Fields, DVLC and panretinal photocoagulation. Eye (Lond) 1992;6(Pt 6):623-625.
196. Pahor D. Visual field loss after argon laser panretinal photocoagulation in diabetic retinopathy: Full-versus mild-scatter coagulation. Int Ophthalmol 1998;22:313-319.
197. Buckley S, Jenkins L, Benjamin L. Field loss after pan retinal photocoagulation with diode and argon lasers. Doc Ophthalmol 1992;82:317-322.
198. Hulbert MF, Vernon SA. Passing the DVLC field regulations following bilateral pan-retinal photocoagulation in diabetics. Eye (Lond) 1992;6(Pt 5):456-460.
199. Mackie SW, Webb LA, Hutchison BM, Hammer HM, Barrie T, Walsh G. How much blame can be placed on laser photocoagulation for failure to attain driving standards? Eye 1995;9(Pt 4):517-525.
200. Tong L, Vernon SA. Passing the DVLA field regulations following bilateral macular photocoagulation in diabetics. Eye 2000;14(Pt 1):35-38.
201. Vernon SA, Bhagey J, Boraik M, El-Defrawy H. Long-term review of driving potential following bilateral panretinal photocoagulation for proliferative diabetic retinopathy. Diabet Med 2009;26:97-99.
202. Canning C, Polkinghorne P, Ariffin A, Gregor Z. Panretinal laser photocoagulation for proliferative diabetic retinopathy: The effect of laser wavelength on macular function. Br J Ophthalmol 1991;75:608-610.
203. Patel JI, Jenkins L, Benjamin L, Webber S. Dilated pupils and loss of accommodation following diode panretinal photocoagulation with sub-tenon local anaesthetic in four cases. Eye 2002;16:628-632.
204. McDonald HR, Schatz H. Macular edema following panretinal photocoagulation. Retina 1985;5:5-10.
205. McDonald HR, Schatz H. Visual loss following panretinal photocoagulation for proliferative diabetic retinopathy. Ophthalmology 1985;92:388-393.
206. François J, Cambie E. Further vision deterioration after argon laser photocoagulation in diabetic retinopathy. Ophthalmologica 1976;173:28-39.
207. Meyers SM. Macular edema after scatter laser photocoagulation for proliferative diabetic retinopathy. Am J Ophthalmol 1980;90:210-216.
208. Huamonte FU, Peyman GA, Goldberg MF, Locketz A. Immediate fundus complications after retinal scatter photocoagulation. I. Clinical picture and pathogenesis. Ophthalmic Surg 1976;7:88-99.
209. Writing Committee for the Diabetic Retinopathy Clinical Research Network, Fong DS, Strauber SF, Aiello LP, Beck RW, Callanan DG, et al. Comparison of the modified Early Treatment Diabetic Retinopathy Study and mild macular grid laser photocoagulation strategies for diabetic macular edema. Arch Ophthalmol 2007;125:469-480.
210. Blumenkranz MS, Yellachich D, Andersen DE, Wiltberger MW, Mordaunt D, Marcellino GR, et al. Semiautomated patterned scanning laser for retinal photocoagulation. Retina 2006;26:370-376.
211. Shimura M, Yasuda K, Nakazawa T, Tamai M. Visual dysfunction after panretinal photocoagulation in patients with severe diabetic retinopathy and good vision. Am J Ophthalmol 2005;140:8-15.
212. Maeshima K, Utsugi-Sutoh N, Otani T, Kishi S. Progressive enlargement of scattered photocoagulation scars in diabetic retinopathy. Retina 2004;24:507-511.
213. Aiello LM. Perspectives on diabetic retinopathy. Am J Ophthalmol 2003;136:122-135.
214. Fluorescein angiographic risk factors for progression of diabetic retinopathy. ETDRS report number 13. Early Treatment Diabetic Retinopathy Study Research Group. Ophthalmology 1991;98(Suppl 5):834-840.
215. Mitchell P, Wong TY; Diabetic Macular Edema Treatment Guideline Working Group. Management paradigms for diabetic macular edema. Am J Ophthalmol 2014;157:505-513.
216. ICO Guidelines for Diabetic Eye Care. Available from: http:// www. icoph. org/downloads/ICOGuidelinesforDiabeticEyeCare. pdf. [Last accessed on 2014 Apr 12].
217. Blankenship GW. Diabetic macular edema and argon laser photocoagulation: A prospective randomized study. Ophthalmology 1979;86:69-78.
218. Early photocoagulation for diabetic retinopathy. ETDRS report number 9. Early Treatment Diabetic Retinopathy Study Research Group. Ophthalmology 1991;98:766-785.
219. Akduman L, Olk RJ. Subthreshold (invisible) modified grid diode laser photocoagulation in diffuse diabetic macular edema (DDME). Ophthalmic Surg Lasers 1999;30:706-714.
220. Friberg TR, Karatza EC. The treatment of macular disease using a micropulsed and continuous wave 810-nm diode laser. Ophthalmology 1997;104:2030-2038.
221. Moorman CM, Hamilton AM. Clinical applications of the MicroPulse diode laser. Eye 1999;13(Pt 2):145-150.
222. Stanga PE, Reck AC, Micropulse laser in the treatment of diabetic macular edema. Semin Ophthalmol 1999;14:210-213.
223. Friberg TR. Infrared micropulsed laser treatment for diabetic macular edema-Subthreshold versus threshold lesions. Semin Ophthalmol 2001;16:19-24.
224. Olk RJ, Akduman L. Minimal intensity diode laser (810 nanometer) photocoagulation (MIP) for diffuse diabetic macular edema (DDME). Semin Ophthalmol 2001;16:25-30.
225. Laursen ML, Moeller F, Sander B, Sjoelie AK. Subthreshold micropulse diode laser treatment in diabetic macular oedema. Br J Ophthalmol 2004;88:1173-1179.
226. Luttrull JK, Musch DC, Mainster MA. Subthreshold diode micropulse photocoagulation for the treatment of clinically significant diabetic macular oedema. Br J Ophthalmol 2005;89:74-80.
227. Bandello F, Polito A, Del Borrello M, Zemella N, Isola M. "Light" versus "classic" laser treatment for clinically significant diabetic macular oedema. Br J Ophthalmol 2005;89:864-870.
228. Luttrull JK, Spink CJ. Serial optical coherence tomography of subthreshold diode laser micropulse photocoagulation for diabetic macular edema. Ophthalmic Surg Lasers Imaging 2006;37:370-377.
229. Sivaprasad S, Sandhu R, Tandon A, Sayed-Ahmed K, McHugh DA. Subthreshold micropulse diode laser photocoagulation for clinically significant diabetic macular oedema: A three-year follow up. Clin Experiment Ophthalmol 2007;35:640-644.
230. Figueira J, Khan J, Nunes S, Sivaprasad S, Rosa A, de Abreu JF, et al. Prospective randomised controlled trial comparing sub-threshold micropulse diode laser photocoagulation and conventional green laser for clinically significant diabetic macular oedema. Br J Ophthalmol 2009;93:1341-1344.
231. Vujosevic S, Bottega E, Casciano M, Pilotto E, Convento E, Midena E. Microperimetry and fundus autofluorescence in diabetic macular edema: Subthreshold micropulse diode laser versus modified early treatment diabetic retinopathy study laser photocoagulation. Retina 2010;30:908-916.
232. Diabetic Retinopathy Clinical Research Network. A randomized trial comparing intravitreal triamcinolone acetonide and focal/ grid photocoagulation for diabetic macular edema. Ophthalmology 2008;115:1447-1449.
233. Diabetic Retinopathy Clinical Research Network (DRCR. net), Beck RW, Edwards AR, Aiello LP, Bressler NM, Ferris F, et al. Three-year follow-up of a randomized trial comparing focal/ grid photocoagulation and intravitreal triamcinolone for diabetic macular edema. Arch Ophthalmol 2009;127:245-251.
234. Gillies MC, Simpson JM, Gaston C, Hunt G, Ali H, Zhu M, et al. Five-year results of a randomized trial with open-label extension of triamcinolone acetonide for refractory diabetic macular edema. Ophthalmology 2009;116:2182-2187.
235. Lam DS, Chan CK, Mohamed S, Lai TY, Lee VY, Liu DT, et al. Intravitreal triamcinolone plus sequential grid laser versus triamcinolone or laser alone for treating diabetic macular edema: Six-month outcomes. Ophthalmology 2007;114:2162-2167.
236. Gillies MC, McAllister IL, Zhu M, Wong W, Louis D, Arnold JJ, et al. Pretreatment with intravitreal triamcinolone before laser for diabetic macular edema: 6-month results of a randomized, placebo-controlled trial. Invest Ophthalmol Vis Sci 2010;51:2322-2328.
237. Diabetic Retinopathy Clinical Research Network, Chew E, Strauber S, Beck R, Aiello LP, Antoszyk A, et al. Randomized trial of peribulbar triamcinolone acetonide with and without focal photocoagulation for mild diabetic macular edema: A pilot study. Ophthalmology 2007;114:1190-1196.
238. Gillies MC, Simpson JM, Billson FA, Luo W, Penfold P, Chua W, et al. Safety of an intravitreal injection of triamcinolone: Results from a randomized clinical trial. Arch Ophthalmol 2004;122:336-340.
239. Quiram PA, Gonzales CR, Schwartz SD. Severe steroid-induced glaucoma following intravitreal injection of triamcinolone acetonide. Am J Ophthalmol 2006;141:580-582.
240. Haller JA, Kuppermann BD, Blumenkranz MS, Williams GA, Weinberg DV, Chou C, et al. Randomized controlled trial of an intravitreous dexamethasone drug delivery system in patients with diabetic macular edema. Arch Ophthalmol 2010;128:289-296.
241. Campochiaro PA, Hafiz G, Shah SM, Bloom S, Brown DM, Busquets M, et al. Sustained ocular delivery of fluocinolone acetonide by an intravitreal insert. Ophthalmology 2010;117:1393-1399. e3.
242. Campochiaro PA, Brown DM, Pearson A, Chen S, Boyer D, Ruiz-Moreno J, et al. Sustained delivery fluocinolone acetonide vitreous inserts provide benefit for at least 3 years in patients with diabetic macular edema. Ophthalmology 2012;119:2125-2132.
243. Adamis AP, Miller JW, Bernal MT, D'Amico DJ, Folkman J, Yeo TK, et al. Increased vascular endothelial growth factor levels in the vitreous of eyes with proliferative diabetic retinopathy. Am J Ophthalmol 1994 15;118:445-450.
244. Cunningham ET Jr. , Adamis AP, Altaweel M, Aiello LP, Bressler NM, D'Amico DJ, et al. A phase II randomized double-masked trial of pegaptanib, an anti-vascular endothelial growth factor aptamer, for diabetic macular edema. Ophthalmology 2005;112:1747-1757.
245. Nguyen QD, Shah SM, Heier JS, Do DV, Lim J, Boyer D, et al. Primary end point (Six Months) results of the ranibizumab for edema of the mAcula in diabetes (READ-2) study. Ophthalmology 2009;116:2175-2181. e1.
246. Nguyen QD, Shah SM, Khwaja AA, Channa R, Hatef E, Do DV, et al. Two-year outcomes of the ranibizumab for edema of the mAcula in diabetes (READ-2) study. Ophthalmology 2010;117:2146-2151.
247. Massin P, Bandello F, Garweg JG, Hansen LL, Harding SP, Larsen M, et al. Safety and efficacy of ranibizumab in diabetic macular edema (RESOLVE Study): A 12-month, randomized, controlled, double-masked, multicenter phase II study. Diabetes Care 2010;33:2399-2405.
248. Mitchell P, Bandello F, Schmidt-Erfurth U, Lang GE, Massin P, Schlingemann RO, et al. The RESTORE study: Ranibizumab monotherapy or combined with laser versus laser monotherapy for diabetic macular edema. Ophthalmology 2011;118:615-625.
249. Diabetic Retinopathy Clinical Research Network, Elman MJ, Aiello LP, Beck RW, Bressler NM, Bressler SB, et al. Randomized trial evaluating ranibizumab plus prompt or deferred laser or triamcinolone plus prompt laser for diabetic macular edema. Ophthalmology 2010;117:1064-1077. e35.
250. Goyal S, Lavalley M, Subramanian ML. Meta-analysis and review on the effect of bevacizumab in diabetic macular edema. Graefes Arch Clin Exp Ophthalmol 2011;249:15-27.
251. Yilmaz T, Cordero-Coma M, Gallagher MJ, Teasley LA. Systematic review of intravitreal bevacizumab injection for treatment of primary diabetic macular oedema. Acta Ophthalmol 2011;89:709-717.
252. Michaelides M, Kaines A, Hamilton RD, Fraser-Bell S, Rajendram R, Quhill F, et al. A prospective randomized trial of intravitreal bevacizumab or laser therapy in the management of diabetic macular edema (BOLT study) 12-month data: Report 2. Ophthalmology 2010;117:1078-1086. e2.
253. Arevalo JF, Sanchez JG, Wu L, Maia M, Alezzandrini AA, Brito M, et al. Primary intravitreal bevacizumab for diffuse diabetic macular edema: The Pan-American Collaborative Retina Study Group at 24 months. Ophthalmology 2009;116:1488-1497, 1497. e1.
254. Lam DS, Lai TY, Lee VY, Chan CK, Liu DT, Mohamed S, et al. Efficacy of 1. 25 MG versus 2. 5 MG intravitreal bevacizumab for diabetic macular edema: Six-month results of a randomized controlled trial. Retina 2009;29:292-299.
255. Ahmadieh H, Ramezani A, Shoeibi N, Bijanzadeh B, Tabatabaei A, Azarmina M, et al. Intravitreal bevacizumab with or without triamcinolone for refractory diabetic macular edema; a placebo-controlled, randomized clinical trial. Graefes Arch Clin Exp Ophthalmol 2008;246:483-489.
256. Soheilian M, Ramezani A, Obudi A, Bijanzadeh B, Salehipour M, Yaseri M, et al. Randomized trial of intravitreal bevacizumab alone or combined with triamcinolone versus macular photocoagulation in diabetic macular edema. Ophthalmology 2009;116:1142-1150.
257. Solaiman KA, Diab MM, Abo-Elenin M. Intravitreal bevacizumab and/or macular photocoagulation as a primary treatment for diffuse diabetic macular edema. Retina 2010;30:1638-1645.
258. Stewart MW, Rosenfeld PJ. Predicted biological activity of intravitreal VEGF Trap. Br J Ophthalmol 2008;92:667-668.
259. Do DV, Nguyen QD, Shah SM, Browning DJ, Haller JA, Chu K, et al. An exploratory study of the safety, tolerability and bioactivity of a single intravitreal injection of vascular endothelial growth factor Trap-Eye in patients with diabetic macular oedema. Br J Ophthalmol 2009;93:144-149.
260. Do DV, Nguyen QD, Boyer D, Schmidt-Erfurth U, Brown DM, Vitti R, et al. One-year outcomes of the da Vinci Study of VEGF Trap-Eye in eyes with diabetic macular edema. Ophthalmology 2012;119:1658-1665.
261. Lanzagorta-Aresti A, Palacios-Pozo E, Menezo Rozalen JL, Navea-Tejerina A. Prevention of vision loss after cataract surgery in diabetic macular edema with intravitreal bevacizumab: A pilot study. Retina 2009;29:530-555.
262. Akinci A, Muftuoglu O, Altinsoy A, Ozkilic E. Phacoemulsification with intravitreal bevacizumab and triamcinolone acetonide injection in diabetic patients with clinically significant macular edema and cataract. Retina 2011;31:755-758.
263. Fard MA, Yazdanei Abyane A, Malihi M. Prophylactic intravitreal bevacizumab for diabetic macular edema (thickening) after cataract surgery: Prospective randomized study. Eur J Ophthalmol 2011;21:276-281.
264. Ishibashi T, Miki K, Sorgente N, Patterson R, Ryan SJ. Effects of intravitreal administration of steroids on experimental subretinal neovascularization in the subhuman primate. Arch Ophthalmol 1985;103:708-711.
265. Danis RP, Bingaman DP, Yang Y, Ladd B. Inhibition of preretinal and optic nerve head neovascularization in pigs by intravitreal triamcinolone acetonide. Ophthalmology 1996;103:2099-2104.
266. Ciulla TA, Criswell MH, Danis RP, Hill TE. Intravitreal triamcinolone acetonide inhibits choroidal neovascularization in a laser-treated rat model. Arch Ophthalmol 2001;119:399-404.
267. Wang YS, Friedrichs U, Eichler W, Hoffmann S, Wiedemann P. Inhibitory effects of triamcinolone acetonide on bFGF-induced migration and tube formation in choroidal microvascular endothelial cells. Graefes Arch Clin Exp Ophthalmol 2002;240:42-48.
268. Jonas JB, Hayler JK, Söfker A, Panda-Jonas S. Intravitreal injection of crystalline cortisone as adjunctive treatment of proliferative diabetic retinopathy. Am J Ophthalmol 2001;131:468-471.
269. Nauck M, Karakiulakis G, Perruchoud AP, Papakonstantinou E, Roth M. Corticosteroids inhibit the expression of the vascular endothelial growth factor gene in human vascular smooth muscle cells. Eur J Pharmacol 1998;341:309-315.
270. Brooks HL Jr. , Caballero S Jr. , Newell CK, Steinmetz RL, Watson D, Segal MS, et al. Vitreous levels of vascular endothelial growth factor and stromal-derived factor 1 in patients with diabetic retinopathy and cystoid macular edema before and after intraocular injection of triamcinolone. Arch Ophthalmol 2004;122:1801-1817.
271. Jonas JB, Kreissig I, Söfker A, Degenring RF. Intravitreal injection of triamcinolone for diffuse diabetic macular edema. Arch Ophthalmol 2003;121:57-61.
272. Jonas JB, Söfker A. Intraocular injection of crystalline cortisone as adjunctive treatment of diabetic macular edema. Am J Ophthalmol 2001;132:425-427.
273. Jonas JB. Intravitreal triamcinolone acetonide for treatment of intraocular oedematous and neovascular diseases. Acta Ophthalmol Scand 2005;83:645-663.
274. Jonas JB, Degenring RF, Kamppeter BA. Outcome of eyes undergoing trabeculectomy after intravitreal injections of triamcinolone acetonide. J Glaucoma 2004;13:261.
275. Kuhn F, Barker D. Intravitreal injection of triamcinolone acetonide for diabetic macular edema. Arch Ophthalmol 2004;122:1082-1083.
276. Savage H, Roh M. Safety and efficacy of intravitreal triamcinolone. Arch Ophthalmol 2004;122:1083.
277. Patelli F, Fasolino G, Radice P, Russo S, Zumbo G, DI Tizio FM, et al. Time course of changes in retinal thickness and visual acuity after intravitreal triamcinolone acetonide for diffuse diabetic macular edema with and without previous macular laser treatment. Retina 2005;25:840-845.
278. Larsson J, Zhu M, Sutter F, Gillies MC. Relation between reduction of foveal thickness and visual acuity in diabetic macular edema treated with intravitreal triamcinolone. Am J Ophthalmol 2005;139:802-806.
279. Massin P, Audren F, Haouchine B, Erginay A, Bergmann JF, Benosman R, et al. Intravitreal triamcinolone acetonide for diabetic diffuse macular edema: Preliminary results of a prospective controlled trial. Ophthalmology 2004;111:218-224.
280. Avitabile T, Longo A, Reibaldi A. Intravitreal triamcinolone compared with macular laser grid photocoagulation for the treatment of cystoid macular edema. Am J Ophthalmol 2005;140:695-702.
281. Sutter FK, Simpson JM, Gillies MC. Intravitreal triamcinolone for diabetic macular edema that persists after laser treatment: Three-month efficacy and safety results of a prospective, randomized, double-masked, placebo-controlled clinical trial. Ophthalmology 2004;111:2044-2049.
282. Audren F, Lecleire-Collet A, Erginay A, Haouchine B, Benosman R, Bergmann JF, et al. Intravitreal triamcinolone acetonide for diffuse diabetic macular edema: Phase 2 trial comparing 4 mg vs 2 mg. Am J Ophthalmol 2006;142:794-799.
283. Jonas JB, Kamppeter BA, Harder B, Vossmerbaeumer U, Sauder G, Spandau UH. Intravitreal triamcinolone acetonide for diabetic macular edema: A prospective, randomized study. J Ocul Pharmacol Ther 2006;22:200-207.
284. Audren F, Erginay A, Haouchine B, Benosman R, Conrath J, Bergmann JF, et al. Intravitreal triamcinolone acetonide for diffuse diabetic macular oedema: 6-month results of a prospective controlled trial. Acta Ophthalmol Scand 2006;84:624-630.
285. Lam DS, Chan CK, Mohamed S, Lai TY, Li KK, Li PS, et al. A prospective randomised trial of different doses of intravitreal triamcinolone for diabetic macular oedema. Br J Ophthalmol 2007;91:199-203.
286. Kang SW, Sa HS, Cho HY, Kim JI. Macular grid photocoagulation after intravitreal triamcinolone acetonide for diffuse diabetic macular edema. Arch Ophthalmol 2006;124:653-658.
287. Parke DW. Intravitreal triamcinolone and endophthalmitis. Am J Ophthalmol 2003;136:918-919.
288. Roth DB, Chieh J, Spirn MJ, Green SN, Yarian DL, Chaudhry NA. Noninfectious endophthalmitis associated with intravitreal triamcinolone injection. Arch Ophthalmol 2003;121:1279-1282.
289. Jonas JB, Kreissig I, Spandau UH, Harder B. Infectious and noninfectious endophthalmitis after intravitreal high-dosage triamcinolone acetonide. Am J Ophthalmol 2006;141:579-580.
290. Jonas JB, Degenring RF, Kreissig I, Akkoyun I, Kamppeter BA. Intraocular pressure elevation after intravitreal triamcinolone acetonide injection. Ophthalmology 2005;112:593-598.
291. Konstantopoulos A, Williams CP, Newsom RS, Luff AJ. Ocular morbidity associated with intravitreal triamcinolone acetonide. Eye (Lond) 2007;21:317-320.
292. Lang Y, Leibu R, Shoham N, Miller B, Perlman I. Evaluation of intravitreal kenalog toxicity in humans. Ophthalmology 2007;114:724-731.
293. Bandello F, Polito A, Pognuz DR, Monaco P, Dimastrogiovanni A, Paissios J. Triamcinolone as adjunctive treatment to laser panretinal photocoagulation for proliferative diabetic retinopathy. Arch Ophthalmol 2006;124:643-650.
294. Spandau UH, Derse M, Schmitz-Valckenberg P, Papoulis C, Jonas JB. Dosage dependency of intravitreal triamcinolone acetonide as treatment for diabetic macular oedema. Br J Ophthalmol 2005;89:999-1003.
295. Jonas JB, Degenring RF, Kamppeter BA, Kreissig I, Akkoyun I. Duration of the effect of intravitreal triamcinolone acetonide as treatment for diffuse diabetic macular edema. Am J Ophthalmol 2004;138:158-160.
296. Rodriguez-Coleman H, Yuan P, Kim H, Gravlin L, Srivastava S, Csaky KG, et al. Intravitreal injection of triamcinolone for diffuse macular edema. Arch Ophthalmol 2004;122:1085-1116.
297. Negi AK, Vernon SA, Lim CS, Owen-Armstrong K. Intravitreal triamcinolone improves vision in eyes with chronic diabetic macular oedema refractory to laser photocoagulation. Eye (Lond) 2005;19:747-751.
298. Gibran SK, Cullinane A, Jungkim S, Cleary PE. Intravitreal triamcinolone for diffuse diabetic macular oedema. Eye 2006;20:720-724.
299. Jonas JB, Spandau UH, Kamppeter BA, Vossmerbaeumer U, Harder B, Sauder G. Repeated intravitreal high-dosage injections of triamcinolone acetonide for diffuse diabetic macular edema. Ophthalmology 2006;113:800-804.
300. Kim H, Csaky KG, Gravlin L, Yuan P, Lutz RJ, Bungay PM, et al. Safety and pharmacokinetics of a preservative-free triamcinolone acetonide formulation for intravitreal administration. Retina 2006;26:523-530.
301. Pearson P, Levy B, Comstock T, Fluocinolone Acetonide Implant Study Group. Fluocinolone acetonide intravitreal implant to treat diabetic macular edema: 3-year results of a multi-centre clinical trial. Invest Ophthalmol Vis Sci 2006;47 5442 [E-abstract 5442].
302. Kuppermann BD, Blumenkranz MS, Haller JA, Williams GA, Weinberg DV, Chou C, et al. Randomized controlled study of an intravitreous dexamethasone drug delivery system in patients with persistent macular edema. Arch Ophthalmol 2007;125:309-317.
303. Verma LK, Vivek MB, Kumar A, Tewari HK, Venkatesh P. A prospective controlled trial to evaluate the adjunctive role of posterior subtenon triamcinolone in the treatment of diffuse diabetic macular edema. J Ocul Pharmacol Ther 2004;20:277-284.
304. Bakri SJ, Kaiser PK. Posterior subtenon triamcinolone acetonide for refractory diabetic macular edema. Am J Ophthalmol 2005;139:290-294.
305. Cardillo JA, Melo LA Jr. , Costa RA, Skaf M, Belfort R Jr. , Souza-Filho AA, et al. Comparison of intravitreal versus posterior sub-Tenon's capsule injection of triamcinolone acetonide for diffuse diabetic macular edema. Ophthalmology 2005;112:1557-1563.
306. Bonini-Filho MA, Jorge R, Barbosa JC, Calucci D, Cardillo JA, Costa RA. Intravitreal injection versus sub-Tenon's infusion of triamcinolone acetonide for refractory diabetic macular edema: A randomized clinical trial. Invest Ophthalmol Vis Sci 2005;46:3845-3849.
307. Caldwell RB, Bartoli M, Behzadian MA, El-Remessy AE, Al-Shabrawey M, Platt DH, et al. Vascular endothelial growth factor and diabetic retinopathy: Role of oxidative stress. Curr Drug Targets 2005;6:511-524.
308. Zhang SX, Ma JX. Ocular neovascularization: Implication of endogenous angiogenic inhibitors and potential therapy. Prog Retin Eye Res 2007;26:1-37.
309. Ng EW, Shima DT, Calias P, Cunningham ET Jr. , Guyer DR, Adamis AP. Pegaptanib, a targeted anti-VEGF aptamer for ocular vascular disease. Nat Rev Drug Discov 2006;5:123-132.
310. Gragoudas ES, Adamis AP, Cunningham ET Jr, Feinsod M, Guyer DR; VEGF Inhibition Study in Ocular Neovascularization Clinical Trial Group. Pegaptanib for neovascular age-related macular degeneration. N Engl J Med 2004;351:2805-2816.
311. Adamis AP, Altaweel M, Bressler NM, Cunningham ET Jr. , Davis MD, Goldbaum M, et al. Changes in retinal neovascularization after pegaptanib (Macugen) therapy in diabetic individuals. Ophthalmology 2006;113:23-28.
312. Churchill AJ, Carter JG, Lovell HC, Ramsden C, Turner SJ, Yeung A, et al. VEGF polymorphisms are associated with neovascular age-related macular degeneration. Hum Mol Genet 2006 1;15:2955-2961.
313. Brown DM, Kaiser PK, Michels M, Soubrane G, Heier JS, Kim RY, et al. Ranibizumab versus verteporfin for neovascular age-related macular degeneration. N Engl J Med 2006;355:1432-1444.
314. Chun DW, Heier JS, Topping TM, Duker JS, Bankert JM. A pilot study of multiple intravitreal injections of ranibizumab in patients with center-involving clinically significant diabetic macular edema. Ophthalmology 2006;113:1706-1712.
315. Spaide RF, Fisher YL. Intravitreal bevacizumab (Avastin) treatment of proliferative diabetic retinopathy complicated by vitreous hemorrhage. Retina 2006;26:275-278.
316. Avery RL, Pearlman J, Pieramici DJ, Rabena MD, Castellarin AA, Nasir MA, et al. Intravitreal bevacizumab (Avastin) in the treatment of proliferative diabetic retinopathy. Ophthalmology 2006;113:1695. e1-15.
317. Mason JO 3rd, Nixon PA, White MF. Intravitreal injection of bevacizumab (Avastin) as adjunctive treatment of proliferative diabetic retinopathy. Am J Ophthalmol 2006;142:685-688.
318. Oshima Y, Sakaguchi H, Gomi F, Tano Y. Regression of iris neovascularization after intravitreal injection of bevacizumab in patients with proliferative diabetic retinopathy. Am J Ophthalmol 2006;142:155-158.
319. Grisanti S, Biester S, Peters S, Tatar O, Ziemssen F, Bartz-Schmidt KU; Tuebingen Bevacizumab Study Group. Intracameral bevacizumab for iris rubeosis. Am J Ophthalmol 2006;142:158-160.
320. Avery RL. Regression of retinal and iris neovascularization after intravitreal bevacizumab (Avastin) treatment. Retina 2006;26:352-354.
321. Haritoglou C, Kook D, Neubauer A, Wolf A, Priglinger S, Strauss R, et al. Intravitreal bevacizumab (Avastin) therapy for persistent diffuse diabetic macular edema. Retina 2006;26:999-1005.
322. Arevalo JF, Fromow-Guerra J, Quiroz-Mercado H, Sanchez JG, Wu L, Maia M, et al. Primary intravitreal bevacizumab (Avastin) for diabetic macular edema: Results from the Pan-American Collaborative Retina Study Group at 6-month follow-up. Ophthalmology 2007;114:743-750.
323. Y a n y a l i A , A y t u g B , H o r o z o g l u F , N o h u t c u A F . Bevacizumab (Avastin) for diabetic macular edema in previously vitrectomized eyes. Am J Ophthalmol 2007;144:124-126.
324. Isaacs TW, Barry C. Rapid resolution of severe disc new vessels in proliferative diabetic retinopathy following a single intravitreal injection of bevacizumab (Avastin). Clin Experiment Ophthalmol 2006;34:802-803.
325. Bakri SJ, Donaldson MJ, Link TP. Rapid regression of disc neovascularization in a patient with proliferative diabetic retinopathy following adjunctive intravitreal bevacizumab. Eye (Lond) 2006;20:1474-1475.
326. Diabetic Retinopathy Clinical Research Network, Scott IU, Edwards AR, Beck RW, Bressler NM, Chan CK, et al. A phase II randomized clinical trial of intravitreal bevacizumab for diabetic macular edema. Ophthalmology 2007;114:1860-1867.
327. Ahmadieh H, Shoeibi N, Entezari M, Monshizadeh R. Intravitreal bevacizumab for prevention of early postvitrectomy hemorrhage in diabetic patients: A randomized clinical trial. Ophthalmology 2009;116:1943-1948.
328. Zhao LQ, Zhu H, Zhao PQ, Hu YQ. A systematic review and meta-analysis of clinical outcomes of vitrectomy with or without intravitreal bevacizumab pretreatment for severe diabetic retinopathy. Br J Ophthalmol 2011;95:1216-1222.
329. Rizzo S, Genovesi-Ebert F, Di Bartolo E, Vento A, Miniaci S, Williams G. Injection of intravitreal bevacizumab (Avastin) as a preoperative adjunct before vitrectomy surgery in the treatment of severe proliferative diabetic retinopathy (PDR). Graefes Arch Clin Exp Ophthalmol 2008;246:837-842.
330. Yeoh J, Williams C, Allen P, Buttery R, Chiu D, Clark B, et al. Avastin as an adjunct to vitrectomy in the management of severe proliferative diabetic retinopathy: A prospective case series. Clin Experiment Ophthalmol 2008;36:449-454.
331. Oshima Y, Shima C, Wakabayashi T, Kusaka S, Shiraga F, Ohji M, et al. Microincision vitrectomy surgery and intravitreal bevacizumab as a surgical adjunct to treat diabetic traction retinal detachment. Ophthalmology 2009;116:927-938.
332. Zhang ZH, Liu HY, Hernandez-Da Mota SE, Romano MR, Falavarjani KG, Ahmadieh H, et al. Vitrectomy with or without preoperative intravitreal bevacizumab for proliferative diabetic retinopathy: A meta-analysis of randomized controlled trials. Am J Ophthalmol 2013;156:106-115. e2.
333. Moradian S, Ahmadieh H, Malihi M, Soheilian M, Dehghan MH, Azarmina M. Intravitreal bevacizumab in active progressive proliferative diabetic retinopathy. Graefes Arch Clin Exp Ophthalmol 2008;246:1699-1705.
334. Hernández-Da Mota SE, Nuñez-Solorio SM. Experience with intravitreal bevacizumab as a preoperative adjunct in 23-G vitrectomy for advanced proliferative diabetic retinopathy. Eur J Ophthalmol 2010;20:1047-1052.
335. Gillies MC, Sutter FK, Simpson JM, Larsson J, Ali H, Zhu M. Intravitreal triamcinolone for refractory diabetic macular edema: Two-year results of a double-masked, placebo-controlled, randomized clinical trial. Ophthalmology 2006;113:1533-1538.
336. Falavarjani KG, Nguyen QD. Adverse events and complications associated with intravitreal injection of anti-VEGF agents: A review of literature. Eye 2013;27:787-794.
337. POLICY STATEMENT-Intravitreal Injections-American Academy of Ophthalmology-Board of Directors; November, 2008.
338. Early vitrectomy for severe vitreous hemorrhage in diabetic retinopathy. Two-year results of a randomized trial. Diabetic Retinopathy Vitrectomy Study report 2. The Diabetic Retinopathy Vitrectomy Study Research Group. Arch Ophthalmol 1985;103:1644-1652.
339. Early vitrectomy for severe proliferative diabetic retinopathy in eyes with useful vision. Results of a randomized trial-Diabetic Retinopathy Vitrectomy Study report 3. The Diabetic Retinopathy Vitrectomy Study Research Group. Ophthalmology 1988;95:1307-1320.
340. Early vitrectomy for severe proliferative diabetic retinopathy in eyes with useful vision. Clinical application of results of a randomized trial-Diabetic Retinopathy Vitrectomy Study report
341. The Diabetic Retinopathy Vitrectomy Study Research Group. Ophthalmology 1988;95:1321-1334.
342. Early vitrectomy for severe vitreous hemorrhage in diabetic retinopathy. Four-year results of a randomized trial: Diabetic Retinopathy Vitrectomy Study Report 5. Arch Ophthalmol 1990;108:958-964.
343. Okamoto F, Okamoto Y, Fukuda S, Hiraoka T, Oshika T. Vision-related quality of life and visual function following vitrectomy for proliferative diabetic retinopathy. Am J Ophthalmol 2008;145:1031-1036.
344. Massin P, Duguid G, Erginay A, Haouchine B, Gaudric A. Optical coherence tomography for evaluating diabetic macular edema before and after vitrectomy. Am J Ophthalmol 2003;135:169-177.
345. Otani T, Kishi S. A controlled study of vitrectomy for diabetic macular edema. Am J Ophthalmol 2002;134:214-219.
346. Yamamoto T, Hitani K, Tsukahara I, Yamamoto S, Kawasaki R, Yamashita H, et al. Early postoperative retinal thickness changes and complications after vitrectomy for diabetic macular edema. Am J Ophthalmol 2003;135:14-19.
347. Smiddy WE, Flynn HW Jr. Vitrectomy in the management of diabetic retinopathy. Surv Ophthalmol 1999;43:491-507.
348. Pendergast SD, Hassan TS, Williams GA, Cox MS, Margherio RR, Ferrone PJ, et al. Vitrectomy for diffuse diabetic macular edema associated with a taut premacular posterior hyaloid. Am J Ophthalmol 2000;130:178-186.
349. Ho T, Smiddy WE, Flynn HW Jr. Vitrectomy in the management of diabetic eye disease. Surv Ophthalmol 1992;37:190-202.
350. L'Esperance FA Jr. The role of vitrectomy in the diabetic patient. J Diabet Complications 1987;1:120-121.
351. Kieselbach G. Vitrectomy in florid proliferative diabetic retinopathy. Ophthalmologica 1989;199:141-145.
352. Fabinyi DC, O'Neill EC, Connell PP, Clark JB. Vitreous cavity haemorrhage post-vitrectomy for diabetic eye disease: The effect of perioperative anticoagulation and antiplatelet agents. Clin Experiment Ophthalmol 2011;39:878-884.
353. Mason JO 3rd, Gupta SR, Compton CJ, Frederick PA, Neimkin MG, Hill ML, et al. Comparison of hemorrhagic complications of warfarin and clopidogrel bisulfate in 25-gauge vitrectomy versus a control group. Ophthalmology 2011;118:543-547.
354. Brown JS, Mahmoud TH. Anticoagulation and clinically significant postoperative vitreous hemorrhage in diabetic vitrectomy. Retina 2011;31:1983-1987.
355. Greenberg PB, Tseng VL, Wu WC, Liu J, Jiang L, Chen CK, et al. Prevalence and predictors of ocular complications associated with cataract surgery in United States veterans. Ophthalmology 2011;118:507-514.
356. Hong T, Mitchell P, de Loryn T, Rochtchina E, Cugati S, Wang JJ. Development and progression of diabetic retinopathy 12 months after phacoemulsification cataract surgery. Ophthalmology 2009;116:1510-1514.
357. Squirrell D, Bhola R, Bush J, Winder S, Talbot JF. A prospective, case controlled study of the natural history of diabetic retinopathy and maculopathy after uncomplicated phacoemulsification cataract surgery in patients with type 2 diabetes. Br J Ophthalmol 2002;86:565-571.
358. Mittra RA, Borrillo JL, Dev S, Mieler WF, Koenig SB. Retinopathy progression and visual outcomes after phacoemulsification in patients with diabetes mellitus. Arch Ophthalmol 2000;118:912-917.
359. Chung J, Kim MY, Kim HS, Yoo JS, Lee YC. Effect of cataract surgery on the progression of diabetic retinopathy. J Cataract Refract Surg 2002;28:626-630.
360. Kim SJ, Equi R, Bressler NM. Analysis of macular edema after cataract surgery in patients with diabetes using optical coherence tomography. Ophthalmology 2007;114:881-889.
361. Aiello LM, Wand M, Liang G. Neovascular glaucoma and vitreous hemorrhage following cataract surgery in patients with diabetes mellitus. Ophthalmology 1983;90:814-820.
362. Poliner LS, Christianson DJ, Escoffery RF, Kolker AE, Gordon ME. Neovascular glaucoma after intracapsular and extracapsular cataract extraction in diabetic patients. Am J Ophthalmol 1985;100:637-643.
363. Tsopelas N, Kokolakis N, Droutsas D, Theodossiadis G. Extracapsular cataract extraction in diabetic eyes. The role of YAG laser capsulotomy. Doc Ophthalmol 1995;91:17-24.
364. Dowler JG, Hykin PG, Lightman SL, Hamilton AM. Visual acuity following extracapsular cataract extraction in diabetes: A meta-analysis. Eye 1995;9(Pt 3):313-317.
365. Dowler JG, Hykin PG, Hamilton AM. Phacoemulsification versus extracapsular cataract extraction in patients with diabetes. Ophthalmology 2000;107:457-462.
366. Schatz H, Atienza D, McDonald HR, Johnson RN. Severe diabetic retinopathy after cataract surgery. Am J Ophthalmol 1994;117:314-321.
367. Liu Y, Luo L, He M, Liu X. Disorders of the blood-aqueous barrier after phacoemulsification in diabetic patients. Eye (Lond) 2004;18:900-904.
368. Patel JI, Hykin PG, Cree IA. Diabetic cataract removal: Postoperative progression of maculopathy-Growth factor and clinical analysis. Br J Ophthalmol 2006;90:697-701.
369. Henricsson M, Heijl A, Janzon L. Diabetic retinopathy before and after cataract surgery. Br J Ophthalmol 1996;80:789-793.
370. Romero-Aroca P, Fernández-Ballart J, Almena-Garcia M, Méndez-Marín I, Salvat-Serra M, Buil-Calvo JA. Nonproliferative diabetic retinopathy and macular edema progression after phacoemulsification: Prospective study. J Cataract Refract Surg 2006;32:1438-1444.
371. Chew EY, Benson WE, Remaley NA, Lindley AA, Burton TC, Csaky K, et al. Results after lens extraction in patients with diabetic retinopathy: Early treatment diabetic retinopathy study report number 25. Arch Ophthalmol 1999;117:1600-1606.
372. Rajavi Z, Katibeh M, Ziaei H, Fardesmaeilpour N, Sehat M, Ahmadieh H, et al. Rapid assessment of avoidable blindness in Iran. Ophthalmology 2011;118:1812-1818.